Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Pharmacists should counsel users of medical cannabis, but should they be dispensing it?

Grootendorst P, Ranjithan R.

Can Pharm J (Ott). 2018 Dec 12;152(1):10-13. doi: 10.1177/1715163518814273. eCollection 2019 Jan-Feb. No abstract available.

2.

Estimating the clinical cost of drug development for orphan versus non-orphan drugs.

Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P.

Orphanet J Rare Dis. 2019 Jan 10;14(1):12. doi: 10.1186/s13023-018-0990-4.

3.

Intellectual Property Protection and Drug Plan Coverage: Evidence From Ontario.

Grootendorst P, Shim M, Falconi A, Robinson T, Lexchin J.

Int J Health Serv. 2018 Oct;48(4):702-715. doi: 10.1177/0020731418789610. Epub 2018 Jul 24.

PMID:
30040005
4.

Uptake and impact of regulated pharmacy technicians in Ontario community pharmacies.

Grootendorst P, Shim M, Tieu J.

Can Pharm J (Ott). 2018 Apr 2;151(3):197-202. doi: 10.1177/1715163518768009. eCollection 2018 May-Jun.

5.

Impact of depression and recreational drug use on emergency department encounters and hospital admissions among people living with HIV in Ontario: A secondary analysis using the OHTN cohort study.

Choi SKY, Boyle E, Cairney J, Grootendorst P, Gardner S, Collins EJ, Kendall C, Rourke SB; OHTN Cohort Study.

PLoS One. 2018 Apr 9;13(4):e0195185. doi: 10.1371/journal.pone.0195185. eCollection 2018.

6.

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology.

Jayasundara K, Krahn M, Mamdani M, Hoch JS, Grootendorst P.

Pharmacoecon Open. 2017 Sep;1(3):167-173. doi: 10.1007/s41669-017-0022-7.

7.

Estimating chronic hepatitis C prognosis using transient elastography-based liver stiffness: A systematic review and meta-analysis.

Erman A, Sathya A, Nam A, Bielecki JM, Feld JJ, Thein HH, Wong WWL, Grootendorst P, Krahn MD.

J Viral Hepat. 2018 May;25(5):502-513. doi: 10.1111/jvh.12846. Epub 2018 Jan 24. Review.

PMID:
29239068
8.

The case for an essential medicines list for Canada.

Eom G, Grootendorst P, Duffin J.

CMAJ. 2016 Dec 6;188(17-18):E499-E503. Epub 2016 Jun 13. No abstract available.

9.

Clinical and microbiological epidemiology of early and late infectious complications among solid-organ transplant recipients requiring hospitalization.

Hamandi B, Husain S, Grootendorst P, Papadimitropoulos EA.

Transpl Int. 2016 Sep;29(9):1029-38. doi: 10.1111/tri.12808. Epub 2016 Jul 11.

10.

Economic evaluation of vaccines in Canada: A systematic review.

Chit A, Lee JK, Shim M, Nguyen VH, Grootendorst P, Wu J, Van Exan R, Langley JM.

Hum Vaccin Immunother. 2016 May 3;12(5):1257-64. doi: 10.1080/21645515.2015.1137405. Epub 2016 Feb 18. Review.

11.

Canada's New Generic Pricing Policy: A Reasoned Approach to a Challenging Problem.

Hollis A, Grootendorst P.

Healthc Policy. 2015 Aug;11(1):10-4.

12.

Validation of Six Short and Ultra-short Screening Instruments for Depression for People Living with HIV in Ontario: Results from the Ontario HIV Treatment Network Cohort Study.

Choi SK, Boyle E, Burchell AN, Gardner S, Collins E, Grootendorst P, Rourke SB; OHTN Cohort Study Group.

PLoS One. 2015 Nov 13;10(11):e0142706. doi: 10.1371/journal.pone.0142706. eCollection 2015.

13.

A Discrete Choice Experiment (Dce) To Elicit Preferences For Attributes Of A Bedside Pharmacogenetic Test - Preliminary Results.

Bereza BG, Pechlivanoglou P, Coyle D, Wells G, So D, Grootendorst P, Papadimitropoulos M.

Value Health. 2015 Nov;18(7):A399. doi: 10.1016/j.jval.2015.09.916. Epub 2015 Oct 20. No abstract available.

14.

Cost Consequence Analysis of Implementing the Low Risk Ankle Rule in Emergency Departments.

Boutis K, von Keyserlingk C, Willan A, Narayanan UG, Brison R, Grootendorst P, Plint AC, Parker M, Goeree R.

Ann Emerg Med. 2015 Nov;66(5):455-463.e4. doi: 10.1016/j.annemergmed.2015.05.027. Epub 2015 Jul 14.

PMID:
26187612
15.

How Effective Is the Medicare Part D Drug Plan?

Grootendorst P.

Ann Intern Med. 2015 Jun 16;162(12):869-70. doi: 10.7326/M15-0953. No abstract available.

PMID:
26075759
16.

Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.

Li Y, Abbaspour MR, Grootendorst PV, Rauth AM, Wu XY.

Eur J Pharm Biopharm. 2015 Aug;94:170-9. doi: 10.1016/j.ejpb.2015.04.028. Epub 2015 May 16.

PMID:
25986587
17.

The opportunity cost of capital: development of new pharmaceuticals.

Chit A, Chit A, Papadimitropoulos M, Krahn M, Parker J, Grootendorst P.

Inquiry. 2015 May 1;52. pii: 0046958015584641. doi: 10.1177/0046958015584641. Print 2015.

18.

Intended and unintended effects of restrictions on the sale of cigarillos to youth: evidence from Canada.

Nguyen HV, Grootendorst P.

Tob Control. 2015 Jul;24(4):382-8. doi: 10.1136/tobaccocontrol-2013-051387. Epub 2014 Mar 7.

PMID:
24610053
19.

Effect of the Low Risk Ankle Rule on the frequency of radiography in children with ankle injuries.

Boutis K, Grootendorst P, Willan A, Plint AC, Babyn P, Brison RJ, Sayal A, Parker M, Mamen N, Schuh S, Grimshaw J, Johnson D, Narayanan U.

CMAJ. 2013 Oct 15;185(15):E731-8. doi: 10.1503/cmaj.122050. Epub 2013 Aug 12.

20.

Toward more specific and transparent research and development costs: the case of seasonal influenza vaccines.

Chit A, Parker J, Halperin SA, Papadimitropoulos M, Krahn M, Grootendorst P.

Vaccine. 2014 May 30;32(26):3336-40. doi: 10.1016/j.vaccine.2013.06.055. Epub 2013 Jul 3.

PMID:
23830976
21.

Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis.

de Oliveira C, Nguyen HV, Wijeysundera HC, Wong WW, Woo G, Grootendorst P, Liu PP, Krahn MD.

CMAJ Open. 2013 Jul 25;1(2):E83-90. doi: 10.9778/cmajo.20130003. eCollection 2013 May.

22.

Canada's contribution to global research in cardiovascular diseases.

Nguyen HV, de Oliveira C, Wijeysundera HC, Wong WW, Woo G, Grootendorst P, Liu PP, Krahn MD.

Can J Cardiol. 2013 Jun;29(6):742-6. doi: 10.1016/j.cjca.2012.09.013. Epub 2012 Dec 6. Review.

PMID:
23219608
23.

Canada's laws on pharmaceutical intellectual property: the case for fundamental reform.

Grootendorst P, Bouchard R, Hollis A.

CMAJ. 2012 Mar 20;184(5):543-9. doi: 10.1503/cmaj.110493. Epub 2011 Nov 7. No abstract available.

24.
25.

Economic instruments for obesity prevention: results of a scoping review and modified Delphi survey.

Faulkner GE, Grootendorst P, Nguyen VH, Andreyeva T, Arbour-Nicitopoulos K, Auld MC, Cash SB, Cawley J, Donnelly P, Drewnowski A, Dubé L, Ferrence R, Janssen I, Lafrance J, Lakdawalla D, Mendelsen R, Powell LM, Traill WB, Windmeijer F.

Int J Behav Nutr Phys Act. 2011 Oct 6;8:109. doi: 10.1186/1479-5868-8-109. Review.

26.

Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis.

Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T.

Pharmacoepidemiol Drug Saf. 2011 Aug;20(8):838-48. doi: 10.1002/pds.2132. Epub 2011 Jun 17.

PMID:
21688345
27.

Equity in dental care among Canadian households.

Quiñonez C, Grootendorst P.

Int J Equity Health. 2011 Apr 16;10:14. doi: 10.1186/1475-9276-10-14.

28.

The cost of drug development: a systematic review.

Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D.

Health Policy. 2011 Apr;100(1):4-17. doi: 10.1016/j.healthpol.2010.12.002. Epub 2011 Jan 21. Review.

PMID:
21256615
29.

New approaches to rewarding pharmaceutical innovation.

Grootendorst P, Hollis A, Levine DK, Pogge T, Edwards AM.

CMAJ. 2011 Apr 5;183(6):681-5. doi: 10.1503/cmaj.100375. Epub 2010 Dec 13. No abstract available.

30.

Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature.

Grootendorst P, Piérard E, Shim M.

Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):353-64. doi: 10.1586/erp.09.35.

PMID:
19670996
31.

How should we support pharmaceutical innovation?

Grootendorst P.

Expert Rev Pharmacoecon Outcomes Res. 2009 Aug;9(4):313-20. doi: 10.1586/erp.09.34.

PMID:
19670991
32.

The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data.

Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P.

Value Health. 2009 Sep;12(6):847-56. doi: 10.1111/j.1524-4733.2009.00532.x. Epub 2009 Mar 11.

33.

Proportion of osteoporotic post-menopausal women at increased risk for upper GI adverse events associated with bisphosphonate therapy.

Levine MA, Grootendorst P.

Pharmacoepidemiol Drug Saf. 2000 Sep;9(5):367-70. doi: 10.1002/1099-1557(200009/10)9:5<367::AID-PDS515>3.0.CO;2-O.

PMID:
19025841
34.

Validation of a prediction model to estimate health utilities index Mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the hip.

Marshall D, Pericak D, Grootendorst P, Gooch K, Faris P, Frank C, Bellamy N, Torrance G, Feeny D.

Value Health. 2008 May-Jun;11(3):470-7. doi: 10.1111/j.1524-4733.2007.00258.x.

35.

Becoming the best mom that I can: women's experiences of managing depression during pregnancy--a qualitative study.

Bennett HA, Boon HS, Romans SE, Grootendorst P.

BMC Womens Health. 2007 Sep 11;7:13.

36.
37.

The effects of coxib formulary restrictions on analgesic use and cost: regional evidence from Canada.

Marshall DA, Willison DJ, Grootendorst P, LeLorier J, Maclure M, Kulin NA, Sheehy OE, Warren L, Sykora K, Rahme E.

Health Policy. 2007 Nov;84(1):1-13. Epub 2007 Jun 13.

PMID:
17570558
38.

Effect of copayments on drug use in the presence of annual payment limits.

Kephart G, Skedgel C, Sketris I, Grootendorst P, Hoar J.

Am J Manag Care. 2007 Jun;13(6 Pt 2):328-34.

39.

A model to estimate health utilities index mark 3 utility scores from WOMAC index scores in patients with osteoarthritis of the knee.

Grootendorst P, Marshall D, Pericak D, Bellamy N, Feeny D, Torrance GW.

J Rheumatol. 2007 Mar;34(3):534-42.

PMID:
17343301
40.

Dental insurance, income and the use of dental care in Canada.

Bhatti T, Rana Z, Grootendorst P.

J Can Dent Assoc. 2007 Feb;73(1):57.

41.

Response to pazderka and schroeder.

Grootendorst P, Di Matteo L.

Healthc Policy. 2007 Feb;2(3):95-6. No abstract available.

42.
43.

Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study.

Austin PC, Grootendorst P, Normand SL, Anderson GM.

Stat Med. 2007 Feb 20;26(4):754-68.

PMID:
16783757
44.

Can current electronic systems meet drug safety and effectiveness requirements?

Holbrook A, Grootendorst P, Willison D, Goldsmith C, Sebaldt R, Keshavjee K.

AMIA Annu Symp Proc. 2005:335-9.

46.

Impact of antibiotic administrative restrictions on trends in antibiotic resistance.

Marshall DA, McGeer A, Gough J, Grootendorst P, Buitendyk M, Simonyi S, Green K, Jaszewski B, MacLeod SM, Low DE.

Can J Public Health. 2006 Mar-Apr;97(2):126-31.

PMID:
16620000
47.
48.

Impact of administrative restrictions on antibiotic use and expenditure in Ontario: time series analysis.

Marshall D, Gough J, Grootendorst P, Buitendyk M, Jaszewski B, Simonyi S, Jivraj F, Macleod S.

J Health Serv Res Policy. 2006 Jan;11(1):13-20.

PMID:
16378528
49.

The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.

Grootendorst PV, Marshall JK, Holbrook AM, Dolovich LR, O'Brien BJ, Levy AR.

Health Serv Res. 2005 Oct;40(5 Pt 1):1297-317.

50.

Supplemental Content

Loading ...
Support Center